FDA Inspection 1200074 — Azurity Pharmaceuticals, Inc.
The FDA completed an inspection of Azurity Pharmaceuticals, Inc. on March 2, 2023 in Wilmington, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 2, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wilmington, MA (United States)